| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2022 | Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort | YC Hsu; DW Jun; CY Peng; ML Yeh; H Trinh; GL Wong; SE Kim; CH Chen; H Oh; CH Lin; L Trinh; VW Wong; E Yoon; SB Ahn; D Huang; YK Cho; JY Jeong; SW Jeong; HS Kim; Q Xiw; L Liu; M Riveiro-Barciela; PC Tsai; EV Accarino; H Toyoda; M Enomoto; C Preda; S Marciano; J Hoang; CF Huang; R Kozuka; S Yasuda; D Istratescu; DH Lee; JY Su; YT Huang ; JF Huang; CY Dai; WL Chuang; MF Yuen; A Gadano; R Cheung; SG Lim; M Buti; ML Yu; MH Nguyen | HEPATOLOGY INTERNATIONAL 16, 1297-1307 | |||
| 2019 | Mac-2-Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients with Chronic Hepatitis B or C Infection | T Jun; YC Hsu; S Ogawa; YT Huang ; ML Yeh; CH Tseng; CF Huang; CM Tai; CY Dai; JF Huang; WL Chuang; ML Yu; Y Tanaka; MH Nguyen | Hepatology Communication 3(4), 493-503 | |||
| 2018 | Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti‐viral therapy in patients with chronic hepatitis B | YC Hsu; T Jun; YT Huang ; ML Yeh; CL Lee; SH Cho; JT Lin; ML Yu; MH Nguyen; Y Tanaka | ALIMENTARY PHARMACOLOGY & THERAPEUTICS 48(10), 1128-1137 | |||
| 2020 | Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B | YC Hsu; GLH Wong; CH Chen; CY Peng; ML Yeh; KS Cheung; H Toyoda; CF Huang; H Trinh; Q Xie; M Enomoto; L Liu; S Yasuda; Y Tanaka; R Kozuka; PC Tsai; YT Huang ; C Wong; R Huang; TY Jang; J Hoang; HI Yang ; J Li; DH Lee; H Takahashi; JQ Zhang; E Ogawa; C Zhao; C Liu; N Furusyo; Y Eguchi; C Wong; C Wu; T Kumada; MF Yuen; ML Yu; M Nguyen | American Journal of Gastroenterology 115(2), 271-280 |
